WO2007008541A3 - Cellular cholesterol absorption modifiers - Google Patents

Cellular cholesterol absorption modifiers Download PDF

Info

Publication number
WO2007008541A3
WO2007008541A3 PCT/US2006/026242 US2006026242W WO2007008541A3 WO 2007008541 A3 WO2007008541 A3 WO 2007008541A3 US 2006026242 W US2006026242 W US 2006026242W WO 2007008541 A3 WO2007008541 A3 WO 2007008541A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol absorption
cellular cholesterol
absorption modifiers
modifiers
cellular
Prior art date
Application number
PCT/US2006/026242
Other languages
French (fr)
Other versions
WO2007008541A2 (en
Inventor
Elisabeth M Gardiner
Sergio G Duron
Mark E Massari
Daniel L Severance
Joseph E Semple
Original Assignee
Kalypsys Inc
Elisabeth M Gardiner
Sergio G Duron
Mark E Massari
Daniel L Severance
Joseph E Semple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc, Elisabeth M Gardiner, Sergio G Duron, Mark E Massari, Daniel L Severance, Joseph E Semple filed Critical Kalypsys Inc
Publication of WO2007008541A2 publication Critical patent/WO2007008541A2/en
Publication of WO2007008541A3 publication Critical patent/WO2007008541A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to compounds and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.
PCT/US2006/026242 2005-07-08 2006-07-05 Cellular cholesterol absorption modifiers WO2007008541A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US69765905P 2005-07-08 2005-07-08
US69768605P 2005-07-08 2005-07-08
US69781405P 2005-07-08 2005-07-08
US60/697,659 2005-07-08
US60/697,686 2005-07-08
US60/697,814 2005-07-08
US72764605P 2005-10-17 2005-10-17
US60/727,646 2005-10-17
US78230306P 2006-03-13 2006-03-13
US60/782,303 2006-03-13

Publications (2)

Publication Number Publication Date
WO2007008541A2 WO2007008541A2 (en) 2007-01-18
WO2007008541A3 true WO2007008541A3 (en) 2007-07-26

Family

ID=37637726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/026242 WO2007008541A2 (en) 2005-07-08 2006-07-05 Cellular cholesterol absorption modifiers

Country Status (1)

Country Link
WO (1) WO2007008541A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
RU2490015C2 (en) * 2008-02-22 2013-08-20 Райджел Фармасьютикалз, Инк. Use of 2,4-diaminopyrimidines for treating atherosclerosis
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7061394B2 (en) 2017-03-31 2022-04-28 国立大学法人 長崎大学 Quinoline compounds and anti-RNA virus drugs
JP7357934B2 (en) 2018-04-12 2023-10-10 パーデュー・リサーチ・ファウンデーション benzamide antibacterial agent

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
UY29607A1 (en) 2005-06-20 2007-01-31 Astrazeneca Ab CHEMICAL COMPOUNDS
AR057072A1 (en) 2005-06-22 2007-11-14 Astrazeneca Ab CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS
WO2007008529A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
KR101467723B1 (en) * 2005-11-01 2014-12-03 탈자진 인코포레이티드 Bi-aryl meta-pyrimidine inhibitors of kinases
TW200804347A (en) 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
CA2636077C (en) 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
WO2008003753A1 (en) * 2006-07-07 2008-01-10 Biovitrum Ab (Publ) Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity
CA2659412A1 (en) 2006-07-31 2008-02-07 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
US20110130397A1 (en) * 2006-09-22 2011-06-02 Soongyu Choi Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
AU2007308154A1 (en) * 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
DE102006050515A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
JP5379692B2 (en) * 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
PE20080932A1 (en) * 2006-11-10 2008-07-13 Wyeth Corp N-SUBSTITUTED PIPERIDINYL 4-ARYLSULFONAMIDES AS MODULATORS OF FRIZZLED-RELATED SECRETED PROTEIN 1 (SFRP-1)
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
EP2000140A1 (en) * 2007-06-05 2008-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine or of 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
EP2178852B9 (en) * 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
EP2203436A1 (en) * 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
EP2205548A1 (en) 2007-10-10 2010-07-14 Amgen, Inc Substituted biphenyl gpr40 modulators
WO2009051909A1 (en) * 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
CA2731224A1 (en) * 2008-07-23 2010-01-28 Sanjay A. Desai Inhibitors of the plasmodial surface anion channel as antimalarials
ES2379762T3 (en) 2008-08-02 2012-05-03 Janssen Pharmaceutica N.V. Urotensin II receptor antagonists
JP5548197B2 (en) * 2008-08-08 2014-07-16 ニューヨーク ブラッド センター， インコーポレイテッド Small molecule inhibitors of retrovirus assembly and maturation
EP2321267A2 (en) * 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Monoaryl aminotetralines
JP2012502104A (en) * 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド Aminopyrimidine inhibitors against histamine receptors for the treatment of disease
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US8383094B2 (en) * 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5551707B2 (en) 2008-10-15 2014-07-16 アムジエン・インコーポレーテツド Spirocyclic GPR40 regulator
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
CN102307581B (en) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 Imidazopyrazine SYK inhibitors
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US20100222381A1 (en) * 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
DK2403499T3 (en) 2009-03-02 2019-12-09 Stemsynergy Therapeutics Inc METHODS AND COMPOSITIONS TO USE IN CANCER TREATMENT AND REDUCTION OF WNT-MEDIATED EFFECTS IN A CELL
CN102459179A (en) * 2009-04-27 2012-05-16 艾伦药物公司 Pyridinone antagonists of alpha-4 integrins
CN105853415A (en) 2009-05-12 2016-08-17 罗马克实验室有限公司 Haloalkyl heteroaryl benzamide compounds
WO2010138828A2 (en) * 2009-05-29 2010-12-02 Abbott Laboratories Potassium channel modulators
WO2010150927A1 (en) * 2009-06-25 2010-12-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives
MX341877B (en) 2009-06-26 2016-09-06 Romark Laboratories L C * Compounds and methods for treating influenza.
US20120189579A1 (en) * 2009-07-10 2012-07-26 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
US8673913B2 (en) * 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
CA2792769C (en) 2010-03-11 2018-05-22 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
MX2012010664A (en) 2010-03-17 2013-02-07 Taivex Therapeutics Inc Modulators of hec1 activity and methods therefor.
BR112012027660A2 (en) 2010-04-27 2016-08-16 Astellas Pharma Inc imidazo [1,2-a] pyridine derivatives
KR20110123657A (en) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
CN101899051B (en) * 2010-05-17 2013-03-20 中国人民解放军第二军医大学 1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof
US20120142701A1 (en) * 2010-05-28 2012-06-07 The University Of Hong Kong Compounds and methods for the treatment of proliferative diseases
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
RU2013109143A (en) 2010-08-05 2014-09-10 Амджен Инк. Benzimidazole- and azabenzimidazole-containing compounds that inhibit the kinase of anaplastic lymphoma
US9868728B2 (en) 2010-10-29 2018-01-16 Emory University Quinazoline derivatives, compositions, and uses related thereto
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
DE102010044131A1 (en) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate
SI3366688T1 (en) 2010-12-08 2022-07-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
JP6616057B2 (en) * 2010-12-22 2019-12-04 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Histone acetyltransferase modulators and uses thereof
US8883793B2 (en) * 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
WO2012097196A1 (en) * 2011-01-12 2012-07-19 Acea Biosciences Inc. Pyrazolopyrimidine derivatives and uses as anticancer agents
CN102670625B (en) * 2011-03-18 2014-05-28 中国人民解放军第二军医大学 Application of urea compound
CN106974913A (en) 2011-04-12 2017-07-25 美国卫生和人力服务部 Plasmodium surface anion channel blocker for treating or preventing malaria
KR101369584B1 (en) * 2011-04-19 2014-03-06 일양약품주식회사 Phenyl-isoxazol derivatives and preparation process thereof
WO2012162468A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Thiazol derivatives as pro -matrix metalloproteinase inhibitors
JP6116554B2 (en) * 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Substituted azaheterocycles for the treatment of cancer
AU2012284184B2 (en) 2011-07-18 2017-03-09 Merck Patent Gmbh Benzamides
AU2012284091B2 (en) 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
TWI640519B (en) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Modulators of hec1 activity and methods therefor
CN103254151B (en) * 2012-02-20 2015-10-28 北京大学 Benzo isothiazole 5-LOX and mPGES-1 inhibitor and application
CA2868484A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
CN104428288B (en) * 2012-05-09 2018-03-13 伊泰莲娜多发性硬化症基金会—Imf非营利组织 Gpr17 receptor modulators
ITMI20120786A1 (en) * 2012-05-09 2013-11-10 Fond Italiana Sclerosi M Ultipla Fism Onlu MODULATORS OF THE GPR17 RECEPTOR
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas Pro-neurogenic compounds
TWI598098B (en) 2012-09-27 2017-09-11 興和股份有限公司 Therapeutic agent for dyslipidemia
KR101488583B1 (en) * 2013-02-06 2015-02-03 부산대학교 산학협력단 New compounds having skin whitening activity and medical use thereof
US9616065B2 (en) * 2013-04-16 2017-04-11 Drexel University Compositions useful in treating brain-related diseases or disorders and methods using same
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
JPWO2015046193A1 (en) * 2013-09-25 2017-03-09 塩野義製薬株式会社 Aromatic heterocyclic amine derivatives having TRPV4 inhibitory activity
EP3052480B1 (en) * 2013-09-30 2020-11-11 The Texas A & M University System Compositions associated with and methods of managing neutrophil movement
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
CN103709096B (en) * 2013-12-24 2017-01-18 中国人民解放军第二军医大学 Urea type derivative used as nicotinamide ribose phosphate transferase inhibitor, as well as preparation method and application thereof
JP6701088B2 (en) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
WO2016022460A1 (en) 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
HRP20211877T1 (en) 2014-12-17 2022-03-04 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
JP6936796B2 (en) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド Histone deacetylase heterohalo inhibitor
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
CN108884077A (en) 2016-02-25 2018-11-23 阿森纽荣股份公司 Glycosidase inhibitor
EA201891438A1 (en) 2016-02-25 2019-01-31 Асенейрон С. А. ACID ADDITIVE SALTS DERIVATIVES OF PIPERAZINE
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
MD3570834T2 (en) 2017-01-11 2022-04-30 Alkermes Inc Bicyclic inhibitors of histone deacetylase
US11896591B2 (en) 2017-05-22 2024-02-13 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers
PT3664802T (en) 2017-08-07 2022-05-24 Alkermes Inc Bicyclic inhibitors of histone deacetylase
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US11555012B2 (en) * 2018-11-09 2023-01-17 Nimbus Artemis, Inc. ACLY inhibitors and uses thereof
CN109574920B (en) * 2018-12-25 2022-03-04 药大制药有限公司 3-nitrile-6-cyclopropyl pyridine IDO1 inhibitor and application thereof
CN109627205B (en) * 2019-01-11 2022-04-12 贵州大学 Preparation method and application of carbazolyl isopropanolamine derivatives
CN109627206B (en) * 2019-01-11 2022-04-12 贵州大学 Preparation method and application of carbazolyl isopropanolamine derivatives with chiral centers
EP4211131A1 (en) * 2020-09-11 2023-07-19 The Regents of the University of California Compositions and methods for treating muscular dystrophies
WO2022159445A1 (en) * 2021-01-19 2022-07-28 Metrea Biosciences, Inc. Compounds and methods of activating lipoprotein lipase
GB202206054D0 (en) * 2022-04-26 2022-06-08 Cerevance Ltd Novel Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223593A2 (en) * 1985-11-19 1987-05-27 Glaxo Group Limited Phenoxyalkylcarboxylic acids and esters and their preparation and pharmaceutical formulation
EP0472449A2 (en) * 1990-07-31 1992-02-26 Lipha, Lyonnaise Industrielle Pharmaceutique Substituted sulfonamides, processes for their preparation and medicines containing them
WO2003043985A1 (en) * 2001-11-21 2003-05-30 Novartis Ag Heterocyclic compounds and methods of use
WO2005015988A1 (en) * 2003-07-17 2005-02-24 Schering Corporation Npc1l1 (npc3) and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223593A2 (en) * 1985-11-19 1987-05-27 Glaxo Group Limited Phenoxyalkylcarboxylic acids and esters and their preparation and pharmaceutical formulation
EP0472449A2 (en) * 1990-07-31 1992-02-26 Lipha, Lyonnaise Industrielle Pharmaceutique Substituted sulfonamides, processes for their preparation and medicines containing them
US5476846A (en) * 1990-07-31 1995-12-19 Lipha, Lyonnaise Industrielle Pharmaceutique Substituted sulfonamides, process of preparation and medicines containing same
WO2003043985A1 (en) * 2001-11-21 2003-05-30 Novartis Ag Heterocyclic compounds and methods of use
WO2005015988A1 (en) * 2003-07-17 2005-02-24 Schering Corporation Npc1l1 (npc3) and methods of use thereof

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
RU2490015C2 (en) * 2008-02-22 2013-08-20 Райджел Фармасьютикалз, Инк. Use of 2,4-diaminopyrimidines for treating atherosclerosis
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7061394B2 (en) 2017-03-31 2022-04-28 国立大学法人 長崎大学 Quinoline compounds and anti-RNA virus drugs
JP7357934B2 (en) 2018-04-12 2023-10-10 パーデュー・リサーチ・ファウンデーション benzamide antibacterial agent

Also Published As

Publication number Publication date
WO2007008541A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2007008541A3 (en) Cellular cholesterol absorption modifiers
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
WO2008011557A3 (en) Heteroaryl inhibitors of rho kinase
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
IL187740A0 (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ZA200710604B (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
EP1756106A4 (en) Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2010032875A3 (en) Heterocyclic carboxamide compounds
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1761532A4 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008033562A3 (en) Kinase inhibitor compounds
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2007092622A3 (en) Compositions and methods for treating bone
EP1896458A4 (en) New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2007139871A3 (en) Methods and materials for making simvastatin and related compounds
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06786403

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06786403

Country of ref document: EP

Kind code of ref document: A2